Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady)
the activity between the fat deposits surrounding the heart and the left atrium.
To reduce the amount of EAT, this study will use a medication called Liraglutide. This
medication is known to work on fat deposits and produce weight loss. The investigator is
conducting this study to find out if Liraglutide will reduce the fat deposits surrounding the
participant's heart, and stabilize (and perhaps reduce or eliminate) atrial fibrillation
activity.
Phase
Phase 4
Funding Agency/Sponsor
Other
Disease
Other
Enrollment Eligibility
Inclusion Criteria:
- Male and female, age 18 or older
- Persistent AF defined as continuous AF sustained beyond 7 days (or AF with the
decision to cardiovert before 7 days of enrollment or Paroxysmal AF defined as
recurrent AF (≥2 episodes) that terminates spontaneously within 7 days
- BMI ≥27 kg/m2
- Patient wishes to undergo a catheter ablation procedure for the treatment of atrial
fibrillation
- Receiving follow-up care at the University of Miami
Exclusion Criteria:
- Inability to sign an informed consent
- Patients with longstanding persistent atrial fibrillation of more than 3 years
- Prior ablation for atrial fibrillation
- Patients not appropriate candidates for catheter ablation such as those with AF due to
acute or chronic precipitating medical conditions, for example, hypothyroidism and
hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial
thrombus, class IV heart failure)
- Patients with a life expectancy <1 year
- Patients with a serious medical condition (for example, recent cancer with
chemotherapy or radiation therapy within 4 weeks before entering the study) who have
not recovered from adverse events due to agents administered more than 4 weeks
earlier.
- Known contraindications to Liraglutide, such as the previous history of pancreatitis
or medullary thyroid carcinoma
- Personal or family history of multiple endocrine neoplasias
- Known serious hypersensitivity reaction to Liraglutide
- Patients using, glitazones, sodium-glucose transporters 2 inhibitors (SGLT2i), other
GLP-1 analogs, or DPP4 inhibitors
- Type 1 diabetes, defined by American Diabetes Association criteria, history of
diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to
pancreatitis or pancreatectomy
- Poorly controlled type 2 diabetes with HbA1c > 10%
- Pregnant women
- Women who are breast-feeding or intend to become pregnant